Stock Price & Analysis

Analysis and Insights

To determine whether it’s a good time to buy or sell TWST stock, we need to analyze both technical and fundamental factors.

Technical Analysis:

TWST's stock price has been experiencing a bearish trend recently, with significant resistance around the $46.20 mark. The latest candlestick chart shows a potential reversal pattern, indicating a possible short-term upside.

Valuation Analysis:

TWST currently has a P/E ratio of 54, which is substantially higher than the average for the biotechnology sector, typically around 20-30. This suggests that investors are pricing in high growth expectations, which might not be sustainable if growth slows down.

Sentiment and Analyst Ratings:

Analyst sentiment is mixed. While some analysts remain positive about TWST’s ability to lead in the synthetic biology market, others express concerns about its ability to scale production efficiently. Based on recent analyst ratings, TWST has a consensus buy, but it's important to consider the high-risk/reward profile.

Conclusion:

Given the high valuation and recent volatility, TWST stock might not be the best buy for risk-averse investors at this time. However, if you're willing to accept potential price fluctuations for long-term growth, it could still be a good option. Consider waiting for a price dip or a confirmation of an uptrend before entering the market.

TWST stock is predicted to trade between $35 and $48 in 2025, with potential resistance at Fibonacci levels of $44.43 and $46.16, and support at $38.83 and $37.10. Analysts have mixed opinions, with price targets ranging from $35 to $62, reflecting varying growth expectations. The stock's price movement will likely be influenced by its current position near the Fibonacci pivot of $41.63 and broader market trends.

The S1 support level for TWST Stock is $38.83 ,The R1 resistant level for TWST Stock is $44.43.

As of the end of day on 2025-03-26, the price of TWST Stock was $43.

The target price for TWST Stock according to analyst rating is 54.29, with the highest price target at 62.00 and the lowest at 40.00. Analysts have a Moderate Buy rating on TWST Stock overall.

The market cap of TWST is $2.6B.

Analysis and Insights

To determine whether TWST is overvalued, we analyze its financial performance, valuation metrics, and market sentiment.

Valuation Metrics:

TWST's current valuation metrics show a mixed picture. The stock has a price-to-earnings (P/E) ratio of 7.1, which is lower than some peers, suggesting potential undervaluation. However, the price-to-sales (P/S) ratio of 4.96 indicates a premium relative to its revenue. The price-to-book (P/B) ratio of 5.63 suggests the market is pricing in significant intangible value.

Revenue Growth and Profitability:

TWST has shown consistent revenue growth, with Q1 2025 revenue reaching $88.7 million, up from $75.3 million in Q2 2024. However, net income remains negative, with a Q1 2025 loss of $31.5 million, reflecting ongoing profitability challenges.

Technical Analysis:

The stock's technical indicators show a neutral to bearish trend. The RSI is at 54.93, indicating neither overbought nor oversold conditions. The MACD is slightly negative, suggesting mild bearish momentum. The stock is trading below its 50-day and 200-day moving averages, which could indicate a downtrend.

Analyst Sentiment:

Analyst opinions are mixed, with some maintaining a "Buy" rating and others a "Sell." The average price target suggests upside potential, but the mixed sentiment reflects uncertainty about the company's future performance.

Conclusion:

TWST does not appear significantly overvalued based on its revenue growth and valuation metrics. However, profitability concerns and mixed analyst sentiment warrant caution. Investors should monitor earnings and profitability improvements before making a decision.

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.

Twist Bioscience (TWST) stock is predicted to reach $80 by 2030, driven by strong analyst sentiment and growth in synthetic biology. Recent price target increases by Scotiabank to $62 and Barclays to $58 reflect confidence in the company's momentum.

TWST has a total of 919 employees.